SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Meta Expands AI Training With Employee Activity Tracking Tools 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
REDWOOD CITY, Calif., Feb. 26, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Cowen and Company 36th Annual Healthcare Conference on Tuesday, March 8 at 10:00 am ET in Boston, Massachusetts.
A webcast of the presentation will be available on the Investors page of the Coherus website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239
